Paloma Partners’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Paloma Partners’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-92,509	Closed	-$4.44M	–	2335
2020 Q1	$4.44M	Sell	92,509 -21,645	-19%	-$1.01M	0.25%	51
2019 Q4	$5.36M	Buy	+114,154	New	+$5.05M	0.08%	225
2018 Q1	–	Sell	-18,172	Closed	-$154K	–	2388
2017 Q4	$154K	Buy	+18,172	New	+$223K	﹤0.01%	1763

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Paloma Partners's RARX Position: Q2 2020 in Review

Paloma Partners sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 92,509 shares — an estimated $4.44M sold.

Paloma Partners first reported a position in RARX in Q4 2017 and held it in 3 quarters. The position peaked at $5.36M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Paloma Partners reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Paloma Partners sold 92,509 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $4.44M.
Paloma Partners first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 3 quarters.
Paloma Partners's Ra Pharmaceuticals, Inc. Common Stock position peaked at $5.36M in Q4 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Paloma Partners's 13F filing for Q2 2020, filed 14 Aug 2020.